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Treating muscle disorders poses several challenges to the rapidly evolving field of regenerative medicine. Considerable progress
has been made in isolating, characterizing, and expanding myogenic stem cells and, although we are now envisaging strategies to
generate very large numbers of transplantable cells (e.g., by differentiating induced pluripotent stemcells), limitations directly linked
to the interaction between transplanted cells and the host will continue to hamper a successful outcome. Among these limitations,
host inflammatory and immune responses challenge the critical phases after cell delivery, including engraftment, migration, and
differentiation. Therefore, it is key to study the mechanisms and dynamics that impair the efficacy of cell transplants in order to
develop strategies that can ultimately improve the outcome of allogeneic and autologous stem cell therapies, in particular for severe
disease such as muscular dystrophies. In this review we provide an overview of the main players and issues involved in this process
and discuss potential approaches that might be beneficial for future regenerative therapies of skeletal muscle.
1. Introduction
Stem cell therapies hold promises for a plethora of conditions
involving the loss or damage of resident tissue progeni-
tors, including skeletal muscle. Skeletal muscle is the most
abundant human tissue and its accessibility makes it a good
candidate for protocols based upon the delivery of stem cells
as a medicinal product. Disorders affecting skeletal muscle
can be acute, such as trauma-related tissue damage or loss,
and chronic, such as tissue wasting in muscular dystrophies,
as typical of Duchennemuscular dystrophy (DMD), themost
common paediatric inherited muscle disorder. DMD is an X-
linked progressive and degenerative myopathy characterised
by muscle wasting and weakness, which ultimately leads
to loss of ambulation in puberty, cardiac and respiratory
involvement, and premature death [1].
Different cell therapy strategies have been tested, in
particular for chronic skeletal muscle disorders, using diverse
types of cells with myogenic potential derived from muscle
(e.g., satellite cells/myoblasts, muscle derived stem cells), ves-
sels (e.g., pericytes and their progeny, mesoangioblasts), bone
marrow, blood, or embryonic tissues, including, recently,
induced pluripotent stem cells (reviewed in [2]). Some of
these cells, such as mesoangioblasts, are currently com-
pleting clinical experimentation for DMD. However, the
data obtained from this multitude of studies resulted in
promising but suboptimal efficacy in restoring functional
skeletal muscle tissue. Therefore, there is still no efficacious
cell therapy-based treatment for muscle diseases. The rea-
sons behind this are linked to challenges associated with
the medicinal product (myogenic stem cells) and with the
target tissue, the multinucleated, abundant, and widespread
skeletal muscle [3]. General bottlenecks of cell therapies are
represented by the availability of an adequate number of stem
cells to transplant, which includes problems related to the
harvesting from donors or from the same patient, genetic
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correction (in case of autologous transplant), maintenance of
myogenic potential prior to transplantation, and large scale
amplification in culture under appropriate conditions and by
their compatibility with the host immune system. Specific
hurdles related to skeletal muscle are due to some of the
tissue’s intrinsic features. First of all, skeletal muscle is the
most abundant tissue in the human body (several kilograms
per individual) and hence cell replacement strategies require
high numbers of transplantable progenitors (several million
per kilogram). Moreover, the administration route greatly
influences the extent of grafting [4]. Indeed transplanted cells
undergo a limited, although variable, migration from the site
of injection that decreases the efficiency of the treatment.
Intra-arterial delivery of the cells is an alternative, but it
is limited to cells that have the ability to cross the vessel
wall (such as pericyte-derived mesoangioblasts and CD133+
cells) [2]. This issue might be of minor relevance for the
treatment of localized disorders but remains one of the most
important to be overcome for the treatment of systemic
muscle pathologies.
In addition to the aforementioned problems, a complex
immune response further complicates and impairs the out-
come of cell transplants. Data from myoblast transplantation
studies indicate that 90% of donor cells are cleared within
the first hour after transplantation by cell-mediated immune
responses [5–7]. Moreover, muscles affected by chronic dis-
eases are in a state of persistent inflammation and are char-
acterized by an abundant infiltrate of immune cells that may
hamper extensive grafting, proliferation, and differentiation
of the transplanted stem cells into functional muscle tissue.
The aim of this review is to give a general overview on the
role of the immune system in the context of skeletal muscle
regeneration focusing on the interaction of immune cells and
transplanted stem cells in cell therapy strategies for muscular
dystrophies. Inflammatory myopathies [8] represent another
broad spectrum of muscle disorders with a predominant
immunological aspect. Although in this type of disorder the
immune system plays a primary role in provoking the muscle
pathology, this will not be discussed here as it goes beyond
the scope of this review.
2. Immune Response during
Muscle Regeneration
Skeletal muscle originates from embryonic mesoderm and
each muscle is composed of several muscle fibres (its func-
tional unit). Each myofibre is a large syncytium containing
numerous nuclei within the same cytoplasm [9]. The fibres’
plasma membrane (also known as sarcolemma) is in tight
contact with the satellite cells, the main resident stem cell
population of skeletal muscle [10, 11].The satellite cell niche is
indeed localised between the basement membrane encircling
each myofibre and the fibres’ sarcolemma. Skeletal muscle
has a conspicuous regenerative ability and relatively large
injuries can be repaired in a few weeks. Upon activation
satellite cells produce transit-amplifying progenitors called
myoblasts (which will fuse with preexisting fibres or generate
new fibres) and give also rise to stem cells able to maintain
the pool of undifferentiated satellite cells for further rounds
of regeneration (reviewed in [12]). This regeneration process
is tightly orchestrated and entails the interplay of different cell
types of muscle origin but also inflammatory and immune
cells (Figure 1). Indeed the latter plays a very important role
in all the stages of the process and alterations to any of the
components impair the regenerative response.
2.1. Muscle Regeneration in Acute Injury. In skeletal muscle,
acute injury either by myotoxin injection, freeze, crush, or
exercise-related damage triggers a stereotypical response.
Injury initiates an innate immune response characterized by
proinflammatory cytokines. Soon after damage, a wave of
neutrophils invades the area with a peak in their concentra-
tion at 24 hours followed by a rapid decrease [13]. Neutrophils
release proinflammatory molecules (such as CXCL8 and
interleukin-6 (IL-6)) that recruitmacrophages into the tissue.
Resident macrophages, present in the interstitial spaces of
the epimysium and perimysium, play key roles especially in
the first phases of acute injury [14]. Macrophages are rapidly
activated and polarized towards a M1 inflammatory pheno-
type (“classically activated” macrophages). Neutrophils and
M1 macrophages produce an array of molecules, including
cytokines, chemokines, nitric oxide, and prostaglandins that
sustain and amplify local inflammation [15].
Tumour necrosis factor 𝛼 (TNF𝛼) is the main proinflam-
matory cytokine present upon skeletal muscle damage [16].
It is initially released by degranulation of resident mast cells
followed by infiltrating neutrophils andmacrophages [17, 18].
Importantly, TNF𝛼 promotes activation and proliferation of
satellite cells [19] while inhibiting their differentiation [20–
22]. These effects are mediated by the activation of nuclear
factor kappa B (NF-𝜅B) [23].
Chemokine (C-Cmotif) ligands 2, 3, and 4 (CCL2, CCL3,
and CCL4) are chemoattractant molecules that play a signif-
icant part in muscle regeneration and their receptors, CCR2
and CCR5, are upregulated following skeletal muscle injury
[24, 25]. Data obtained from knock-out mice showed that
CCR2 is required for macrophage invasion of the injury site,
with impaired regeneration in CCR2-null mice in parallel
with a slowed revascularization of the injured area [26].
Moreover, satellite cells and myoblasts constitutively express
CCR1, CCR2, CCR4, and CCR5 [27].
M1 macrophages express the inducible nitric oxide syn-
thase (iNOS) and hence release nitric oxide (NO) in the
injury site. AlthoughNOcandamagemuscle cellmembranes,
it also facilitates tissue debris clearance by targeting them for
phagocytosis [28]. In addition, oxidative stress caused by NO
stimulates satellite cell proliferation [29], a process essential
for muscle regeneration.
Other key molecules present in the inflammatory phase
of muscle regeneration are prostaglandins. These signalling
molecules are derived from the metabolism of arachidonic
acid by cyclooxygenases (COX) and expression of COX-1
and COX-2 is indeed very high in injured muscles [30]. The
effects of prostaglandins have been reported in all the stages
of muscle regeneration, from satellite cells proliferation [31]
to differentiation [32] and fusion [33].
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Figure 1: Dynamics of inflammation and muscle regeneration in acute and chronic injury. Acute muscle injury (a) triggers local release of
chemoattractants that induce PMNs and M1 invasion into the damaged tissue. PMNs and M1 release an array of molecules (such as NO)
that further amplify local inflammation, contributing to debris clearance and SC activation. This initial Th1-driven inflammation is later
overcome by an anti-inflammatory response that coincides with a M1-to-M2 switch. By day 4 Tregs reach the site of injury, modulating
Tconv expansion and activation and SC differentiation through amphiregulin release. M2 andTh2 cytokines reduce local inflammation and
contribute to SCs differentiation, thus promoting the latest stages of muscle regeneration. Upon damage repair, SCs return to quiescence.
Chronic muscle injuries (b) are characterised by persistent inflammation. Muscles feature infiltrates of PMNs, M1 together with M2, Tconv,
and Treg; moreover, the simultaneous release of pro- and anti-inflammatory molecules promotes incomplete tissue regeneration and fibrosis.
The SC pool undergoes depletion due to continuous rounds of activation and differentiation, resulting in terminalmuscle wasting. SC: satellite
cells; PMN: neutrophils; M1:M1macrophages;M2:M2macrophages; Tconv: CD4+ conventional T cell; Tregs: CD4+ Foxp3+ regulatory T cell;
NO: nitric oxide; Red box: Th1-driven response; Green box; Th2-driven response.
The M1-driven tissue inflammation is gradually over-
come by an anti-inflammatory response due to a switch
in macrophage phenotype, from M1 to M2 (“alternatively
activated”) [34]. M2-polarized macrophages are activated
by anti-inflammatory Th2 cytokines such as IL-4, IL-10,
and IL-13 that attenuate the inflammatory response through
M1 deactivation [35]. Moreover, IL-4 and IL-10 act directly
on muscle cells, inducing myogenin expression and sub-
sequent differentiation and fusion [34, 36]. Hence, while
M1 macrophages contribute to creating an inflammatory
environment that helps clearing cell debris and activating
satellite cells, M2 macrophages reduce inflammation and
promote myogenic differentiation.
Although molecules are secreted by immune cells shape
regeneration, the muscle is not a passive bystander. Indeed
it releases a series of cytokines and chemokines collectively
referred to as “myokines” [37] which also include IL-6, TNF𝛼,
and CCL2 [38, 39]. Aside from proinflammatory functions,
IL-6 was demonstrated to have both an autocrine function
on satellite cell proliferation and muscle hypertrophy [40]
and paracrine effects when released into the circulation (on
glucose metabolism and lipolysis) [41].
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2.2. Regeneration in Chronic Muscle Disorders. While acute
muscle injuries are characterized by a self-limiting physi-
ological inflammatory reaction, chronic muscle conditions
are generally associated with persistent inflammation. Recent
data indicate that inflammation plays an active part in the
pathology [42]. Chronic myopathies are a heterogeneous
group of diseases characterized by progressive muscle wast-
ing and includemuscular dystrophies (e.g., DMD),whichwill
be the focus of this review.
The important role of inflammation in muscular dystro-
phies is supported by the efficacy of corticosteroid treatments
in improving muscle strength and function in the short term
in patients [43]. Indeed muscular dystrophies are generally
characterized by an infiltrate of inflammatory neutrophils
and phagocytic M1 macrophages that produce inflammatory
cytokines andNO, as in the case in acute injuries [44]. A hall-
mark of chronic muscle pathologies is the infiltration of M2
macrophages at early stages; this differs from acute muscle
injury, where M2 macrophages invade the tissue only at later
time points. M2 macrophages express the enzyme arginase,
which shares its substrate (arginine) with iNOS expressed
by M1 macrophages and this M1-M2 substrate competition
decreases NO production [44]. M2 macrophages also induce
a Th1-Th2 shift of cytokine production, with an increase of
IL-4 and IL-10, which can deactivate M1 macrophages [35].
ThisTh2-dominated environment also induces the activation
of eosinophils that promote muscle fibrosis through major
basic protein-1-mediated processes [45]. Data obtained from
mdx mice and DMD patients suggest that, besides the innate
immune response, some degree of cellular immunity is also
involved [46, 47]. DMD muscles are in fact characterized
by the presence of infiltrating T cells expressing a highly
conserved peptide in the hypervariable domain of the T-cell
receptor, suggesting a breakdown in peripheral tolerance [46,
48]. Recently, dystrophin-specific T-cell responses have been
described in a considerable proportion of DMD patients.
Of interest, the incidence of such responses was lower
in the cohort of patients receiving deflazacort (a steroid)
than in untreated ones, suggesting that the modulation of
cellular immunity may contribute to the beneficial effect of
corticosteroid treatment [48].
Other chronic disorders characterised by an altered
regenerative and inflammatory pattern in the affected mus-
cles include, for example, the groups of facioscapulohumeral
muscular dystrophy (FSHD) and the limb girdle muscular
dystrophies (LGMDs). Although these disorders are caused
by different genetic alterations, both FSHD and LGMD have
been shown to present clear hallmarks of inflammation
(e.g., in FSHD1A [49] and LGMD2B [50]). However, the
relevance to the onset and progression of the pathology
remains ambiguous.
3. Immunologically Relevant Molecules
Expressed by Muscle Cells
In both physiological and pathological conditions, there is an
active interplay betweenmuscle cells and cells of the immune
system.This interaction is made possible by a shared panel of
soluble and transmembrane molecules that transduce signals
and form functional synapses between the two cell types [51,
52]. Beyond the already discussed soluble factors (cytokines
and chemokines) and their receptors, muscle expresses other
immunologically relevant molecules.
Toll-like receptors (TLRs) are the principal activators of
the innate immune response. TLRs are expressed onmultiple
cell types (such as dendritic cells and macrophages) and
generally respond to “danger signals” (e.g., pathogens and
damage associated molecules) triggering the production of
inflammatory cytokines and chemokines. In vitro studies
demonstrated that murine myotubes express TLR2, TLR4,
TLR5, and TLR9 [53]. Notably, a study showed that TLR3
is expressed in muscle biopsies of patients with chronic
myopathies and that TLR3 activation on human myoblasts
triggers a downstream cascade leading to NF-𝜅B activation
and ultimately IL-8 production [54].
In vitro, myoblasts constitutively expressmajor histocom-
patibility complex I (MHC I), which is upregulated upon
inflammatory stimuli, such as IFN𝛾. IFN𝛾 also induces the
expression of MHC II in muscle cells [55, 56]. In vivo,
muscle fibres do not express MHC I or MHC II under
physiological conditions [57], but they are expressed at high
levels in inflammatory muscle disorders [58]. Due to the
inducible MHC I/II expression, muscle cells are considered
to be nonprofessional antigen presenting cells (APCs) and
thus have the capacity to trigger T-cell-mediated immune
response. In this context, it was demonstrated that human
muscle cells possess all the intracellular machinery required
for antigen processing in the context of MHC I/II presenta-
tion [59, 60]. Moreover, presence of fibroblast growth factor
(FGF) in dystrophicmuscle [61]may on the one hand regulate
proliferation of myogenic progenitors [62] but on the other
hand lead to expression of the MHC class II receptor HLA-
DR, as it has been identified in human mesenchymal stem
cells [63]. Aside fromMHCmolecules, myoblasts can express
a nonclassical MHC I molecule, human leukocyte antigen-
G (HLA-G), under inflammatory conditions [64]. HLA-G is
a molecule with very low polymorphism and it is generally
considered tolerogenic because of its role in maternal-foetal
tolerance [65] and graft acceptance [66].
Canonical costimulatory molecules, such as the CD80
and CD86, required together with MHC for T-cells activa-
tion, have not been identified onmuscle cells [67, 68]. CD40-
CD40 ligand interaction is another key signal required in
both humoral and cellular immunity. CD40 is usually present
on the membrane of APCs and CD40 ligand on activated
CD4+/CD8+ T cells, where it transduces signals for their
stimulation and expansion. CD40 is also found expressed
in other cell types [69, 70], including muscle cells. In vitro,
human myoblasts constitutively express CD40 and its levels
increase upon IFN𝛾 and TNF𝛼 stimulation [67]. In this
cell type, CD40-CD40 ligand interaction leads, among other
effects, to an increase of intracellular adhesion molecule 1
(ICAM-1) expression [71] and hence to interaction with T
cells present in the muscle tissue.
Adhesion molecules have a pivotal function in allow-
ing interaction of muscle cells with immune cells. During
skeletal muscle inflammation, ICAM-1 is expressed by both
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the endothelium of the vessels and by the muscle fibres [51,
72, 73]. ICAM-1 interacts with leukocyte function-associated
antigen 1 (LFA-1), an integrin, which is expressed on T cells.
ICAM-1/LFA-1 interaction leads to T-cell recruitment into
the inflamed tissue (via ICAM-1 expression on endothelial
cells) facilitating myofibre cytotoxicity (through myofiber-
CD8+ T-cell interaction) [74].
In addition, PD-1/PD-L1 binding is thought to play
an important role in suppressing immune responses [75].
Interestingly, expression of programmed death ligand 1
(PD-L1), an immune-inhibitory molecule, is induced in
mesoangioblasts stimulated with proinflammatory cytokines
[76] and in muscle biopsies from patients with idiopathic
inflammatorymyopathies [77]. Based on these findings, these
cells are more likely to perform crucial functions in limiting,
rather than priming, a muscle-directed immune response in
inflammatory settings.
4. Interaction between Immune Cells and
Muscle Stem Cells: In Vitro Studies
A large body of data provides evidence for the important
part played by immune cells in shaping the regenerative
response following muscle damage/injury. We have already
discussed the key cells involved in this process and their
role in promoting repair; however, much less is understood
about the interactions between immune cells and muscle
stem cells. Studies have shown the capacity for macrophages
and macrophage-conditioned medium to enhance myogenic
precursor cell adhesion and migration in vitro [78–80].
Blocking studies revealed pivotal functions for TNF-𝛼 and
high mobility group box 1 (HMGB1) protein likely derived
from macrophages [79, 80].
Dendritic cells (DC, professional APCs) have been iden-
tified in inflammatory infiltrates in muscle biopsies and may
play an essential role in direct activation of antigen specific
T cells [81]. Coculture of DC with myoblasts leads to a
semimature DC phenotype with reduced ability to promote
T-cell activation and proliferation in a cell contact dependent
manner [82].This study provided one of the first observations
thatmuscle progenitor cells have immunemodulatory capac-
ity and could potentially promote a tolerogenic environment.
The adaptive immune response also has a role in inflam-
matory muscle disorders. Following activation by the innate
immune system, dystrophin reactive T cells have been
identified in DMD patients [48]. As such, these T cells
may pose a threat both to autologous gene-corrected cell
therapies and also to allogeneic cellular therapies. One in
vitro study has investigated the effects of T cells on human
mesoangioblasts and vice versa [76]. Despite an increase
in HLA molecules expressed by mesoangioblasts following
stimulation with IFN-𝛾, these cells failed to induce T-cell
proliferation in vitro.Mesoangioblasts expressed lowor negli-
gible levels of the costimulatory molecules CD40, CD80, and
CD86; however, following stimulation with proinflammatory
cytokines significant expression of the inhibitory molecule
PD-L1 was observed.This suggested that mesoangioblasts are
hypoimmunogenic [76]. This study also examined the effects
of mesoangioblasts on T cells and their immunosuppressive
capacity in vitro. Mesoangioblasts suppressed both CD4+
and CD8+ T-cell proliferation in a dose and time dependent
manner but did not induce anergy in T cells. In addition,
mesoangioblasts inhibited T-cell production of proinflam-
matory cytokines. The mechanisms of action identified an
important role for IFN-𝛾 and TNF-𝛼 in activation ofmesoan-
gioblast to become immunosuppressive followed by secretion
of indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2
(PGE-2) to inhibit T-cell proliferation [76]. Similar findings
were obtained using induced pluripotent stem (iPS) cell-
derived mesoangioblast-like cells [83]. In addition, mesoan-
gioblasts show peculiar resistance to T-cell killing, although
they are recognized and killed by allogeneic T cells in an
inflammatorymicroenvironment or upondifferentiation into
myotubes [84].
Aside from the positive effects that muscle stem cells
may have in promoting a tolerogenic environment, there are
negative interactions between these different cell populations.
As discussed previously, neutrophils and macrophages are
required for clearance of cell debris among other functions. In
addition, cytotoxic killing of muscle cells by neutrophils was
also reported [85]. This study identified interactions between
neutrophils and macrophages, which promote macrophage
killing of muscle cells in vitro. Similarly, TLR3 stimulation
of muscle cells in vitro leads to the upregulation of the
activating receptor NKG2D and subsequent natural killer
(NK) mediated lysis of muscle cells [54]. However, it may
be possible to reduce the susceptibility of muscle stem cells
to NK-mediated lysis. Indeed a recent study demonstrated
that prestimulation with IFN-𝛾 can significantly decrease the
susceptibility of allogenic human mesenchymal stem cells to
activated NK-mediated cytotoxicity in vitro [86]. Few studies
have been carried out to investigate the interactions between
these two cell populations highlighting the need for addi-
tional investigation in this area. Importantly, in vivomodels of
muscle degeneration may provide a better understanding of
the interactions between muscle stem cells and immune cells
and howbest to facilitate successful engraftment and function
of stem cells.
5. Studying Immune Response upon
Muscle Stem Cell Transplantation in
Preclinical Models
5.1. Animal Models of Muscular Dystrophies. Animal mod-
els are extremely useful to investigate the pathogenesis of
muscular dystrophies, the contribution of inflammation and
immune responses inmuscle repair and to evaluate safety and
efficacy of novel therapeutic strategies. In particular, several
animal models were developed for muscular dystrophies,
among which the most commonly used is the X-linked mus-
cular dystrophymouse (mdx) carrying nonsense mutation in
exon 23 of the dystrophin gene [87]. For the preclinical valida-
tion of transplanted human myogenic progenitors, immun-
odeficient murine models have been particularly helpful
to minimize xenoreactivity and to facilitate engraftment of
human cells. Several immunodeficient mice modelling DMD
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are available, including the nude/mdx mice [88], lacking the
T-cell compartment, the SCID-mdx mice [89], lacking both
T and B cells, and the recently described NSG-mdx4CV [90],
and Rag2−IL2rb−DMD− mice [91], in which the NK cell
activity is also defective. Dystrophic and immunodeficient
mice are also available for limb-girdle muscular dystrophies
(LGMD), including the alpha-sarcoglycan-null/scid/beige
mouse for LGMD2D (alpha-sarcoglycan deficiency) [92] and
the SCID/BlAJ mouse for LGMD2B (dysferlin deficiency)
[93]. The above mouse models have been used to transplant
nonsyngeneic cells harbouring additional transgenes (e.g.,
GFP), and some of them were also shown to be good recip-
ients for novel human pluripotent stem cell-based protocols
for muscular dystrophies [92, 94].
Among large animal models, the Golden Retriever mus-
cular dystrophy (GRMD) [95, 96] and the Beagle-based
canine X-linked muscular dystrophy (CXMD [97]) mod-
els were used in preclinical studies to demonstrate safety
and efficacy of stem cell-based approaches for muscular
dystrophies [98–100]. These independent studies shared the
systemic delivery of nonmyoblast myogenic stem cells of
mesodermal/mesenchymal origin, that is, mesoangioblasts
[98], mesenchymal stromal cells (MyoD-transduced) [99]
and muscle stem cells [100]. Allogeneic (with immuno-
suppressive therapy) and autologous gene-corrected stem
cells were tested and overall results showed low frequency
of inflammatory infiltrates and absence of anti-dystrophin
antibodies.
Very recently the generation and characterisation of
dystrophin-deficient pigs have been reported [101]. Even if
this model appears to be particularly severe in compari-
son with the human disease progression, it could offer an
additional platform for future studies. Although there are
no dystrophic nonhuman primates, the use of wild type
strains to optimize the design of cell therapy approaches has
been reported. Several immunosuppressive regimen and cell
injection modalities were compared in nonhuman primates
to improve myoblast transplantation [102].
5.2. Stem Cell Transplantation. During the last decade, limi-
tations in myoblast transplantation (detailed in the next sec-
tion) fostered the search for other transplantable myogenic
progenitors [2]. Given the pathological role of inflammation
and immune dysregulation inmuscular dystrophies [103, 104]
and the high risk of rejection documented after myoblasts
transplantation, many groups tried to find a transplantable
cell type which combines myogenic potential together with
anti-inflammatory and immunomodulatory properties. To
this end, bone marrow-derived mesenchymal stromal cells
(MSC, reviewed in [105]) were utilised for muscle regener-
ation [88]. However, a subsequent study showed that MSC
engraftment into dystrophin-deficient mice did not result
in spontaneous differentiation into muscle fibres and in
functional recovery [106].
Mesoangioblasts are pericyte-derived progenitors that
can be isolated fromadultmuscles and are able to differentiate
into muscle fibres in vitro and in vivo upon transplantation
(reviewed in [2]). The finding that allogeneic transplantation
of mouse mesoangioblasts into alpha-sarcoglycan null dys-
trophic mice gave rise to alpha-sarcoglycan positive muscle
fibres suggested that these cells may have some degree of
immune evasion [107]. The immunosuppressive properties
of human mesoangioblasts have been described above [76]
and recent in vitro observations indicated that their immune
privileged phenotype can be partially reverted during inflam-
mation or upon differentiation [84]. A similar mechanism
might be responsible for the negative outcome observed in
a study where the alloreactive response of MSCs led to donor
graft rejection [108]. Thus, although immune privileged
stem/progenitors have regenerative capacity useful to treat
muscle disorders, the survival of allogeneic stem cell progeny
in vivo may still require pharmacological immunomodula-
tion.
In the autologous setting (e.g., gene therapy strategies),
host cells are genetically manipulated to correct or replace
the defective gene. Based on the promising results obtained
in dystrophic animals [109], clinical trials based on AAV-
mediated gene transfer in muscles were designed to treat
patients affected by inherited muscle disorders. However, the
development of cellular and humoral responses specific for
vector components [110] and/or for the transgene [111] posed
important limitations and triggered further research to solve
this issue and develop new gene therapy vectors [2].
One possible solution is the use of regulatory T cells
(Treg) [112]. For instance, expansion of antigen specific
Tregs after vector-mediated gene transfer to the liver leads
to the induction of tolerance to the transgene [113, 114].
Recently, it was demonstrated that a specific subtype of
clonally expandedTreg cells (specifically Foxp3+ CD4+ with a
restrictedTCR repertoire) was enriched inmuscle upon acute
or chronic injury, facilitating a nonimmunological role that
favours tissue repair [115]. The authors proposed that Treg
cells act, at least in part, by regulating the infiltrating myeloid
population and by stimulating satellite cell proliferation
and differentiation via the secretion of the growth factor
amphiregulin [115].
5.3. Limitations of Xenografts. As the field of regenerative
gene and cell therapy progresses and transgene expres-
sion reaches the threshold required for clinical benefit,
the immune response elicited in human muscle remains a
challenging issue that needs to be addressed to enhance the
efficacy of these promising therapeutic approaches. Unfor-
tunately, immunodeficient mice still show limited engraft-
ment and are not able to predict host immune responses.
Thus, further studies are needed to clarify the mechanism
underlying these reactions and to identify potential targets of
immune intervention. Possible options might be transplan-
tation in juvenile mice (where the muscle is less “primed” by
inflammation) [92], neonatal desensitization [116], or evasion
of macrophage killing [117, 118].
Although transplantation of different human stem cell
populations in immunodeficient mice allows studying their
safety and efficacy profile, this assay gives only subopti-
mal results, possibly because of variables other than the
immune system regulating donor cell engraftment. Indeed,
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several species-specific mechanisms of survival, migration,
and expansion and differentiation depend on the direct
interaction with the host environment (e.g., integrins and
other proteins of the extracellular matrix), which in the case
of a xenotransplant will be significantly mismatched. Overall,
experiments in small and large animals paved the way to the
clinical translation of therapeutic strategies based upon the
infusion of healthy donor myogenic cells. These and other
studies are analysed in the next section.
6. From Preclinical Studies to Clinical Trials
Following the promising results observed in mdx mice [119],
a number of clinical trials in the early 1990s tested allogeneic
transplantation of myoblasts to treat muscular dystrophies
(reviewed in [7, 12]). Unfortunately, the outcome was disap-
pointing due to the limited or absent dystrophin expression
and to the limited gain in muscle strength of treated patients
[120]. The major limitations to the success of allogeneic
myoblasts transplantation were the high early mortality
rate and the limited migratory abilities of myoblasts upon
transplantation, together with the host immune reaction.The
group of Tremblay treated dystrophic patients with intra-
muscular injection of allogeneic myoblasts in the absence
of immune suppression and documented acute rejection of
the cells [121]. This group then reported both cellular and
humoral alloreactive responses in rodents, with myoblast-
injected muscles infiltrated by activated CD4+ and CD8+
T lymphocytes and myoblast-reactive antibodies detected
in recipient sera [122]. Thus, specific immune responses
against injected cells were demonstrated and claimed to
explain, at least in part, the suboptimal therapeutic benefits,
suggesting the need for immune suppression to avoid acute
rejection. Several immunosuppressive agents were therefore
tested for their ability to promote myoblast engraftment
in preclinical models. Tacrolimus administration was found
to adequately control immune reactions without affecting
myoblast proliferation and differentiation capacity, both in
mice and in nonhuman primates [102, 123].
Another bottleneck formyoblast engraftment inmicewas
the high mortality rate of the injected cells during the first
three days after transplantation. The early loss of donor cells
was explained on the one hand with the variable viability
of the cell preparation and on the other with inflammation-
mediated events. Neutrophils and macrophages infiltrate
myoblast-injected muscles within a few hours and likely
mediate early cell death before the development of adaptive
immune responses [124]. Interestingly, a study on myoblast
dynamics indicated that only a minority of injected cells
showing stem-cell-like behaviour have the chance to survive
long-term and exert regenerative capacity, suggesting that
immune rejection is not the only limitation of myoblast-
based therapy [125]. Furthermore, other studies excluded a
role for innate immune-mediated rejection [126]. Addition-
ally, ischaemic necrosis of implanted cells was also found to
be an important hurdle to a successful graft [127].The limited
migratory ability of myoblasts required multiple injections in
separated sites in nonhuman primates [102] and represents
a further limitation for the treatment ofmuscular dystrophies
affecting the majority of skeletal muscles, including the
diaphragm.
Although high-density injections of allogeneic myoblasts
under tacrolimus administration led to the development
of new muscle fibres in DMD patients [128], the current
consensus is that myoblasts transplantation can be the elec-
tive treatment only for localized forms of muscles diseases.
Indeed a recent phase I/IIa clinical study trial reported
some benefit using autologous myoblast transplantation in
the cricopharyngeal muscles of 12 adult patients affected by
oculopharyngeal muscular dystrophy (OPMD), an autoso-
mal dominant genetic disease characterized by ptosis and
dysphagia. Safety and tolerability were observed in all the
patients, together with an improvement in the quality of life
score. No functional degradation in swallowing was observed
for 10/12 patients [129]. At variance with most autologous
transplantation strategies, the above study did not require
any genetic correction of the medicinal product, since it
was possible to do a biopsy in several healthy muscles of
the same patients. However, this would not be possible
for most muscular dystrophies and a possible preexisting
immunity against the vector, the mutated protein, or the
newly introduced wild type epitopes needs to be taken into
account, although this might not correlate directly with a
negative outcome [48, 129–131].
The need to overcome the hurdles observed in myoblasts
transplantation studies for DMD prompted several laborato-
ries to identify alternative populations of myogenic cells with
a better profile in terms of expansion, survival, andmigration.
Among these, CD133+ cells and mesoangioblasts have been
tested clinically. The safety of autologous transplantation of
muscle-derived CD133+ cells was tested in eight boys with
DMD in a double-blinded phase I clinical trial and no adverse
events were reported [132]. Future follow-up studies based
upon genetically corrected CD133+ are expected. A first-
in-man phase I/II clinical trial based upon intra-arterial
infusion of donor HLA-matched mesoangioblasts in 5 DMD
boys receiving tacrolimus as immunosuppressive therapy is
currently approaching conclusion at San Raffaele Hospital
(Milan, Italy; EudraCT number 2011-000176-33). Clinical,
biochemical and functional progress of the disease were
followed during the year preceding treatment and were
validated with a cohort of ambulant DMD boys and healthy
controls [133]. Safety is the primary objective of the study and
preliminary results indicate that the treatment is relatively
safe. Indeed no adverse events due to immune suppression
were observed, with good control of the immune response in
the patients (Cossu et al., unpublished results).This study also
provides clinical proof-of-principle for transplantation and
intravascular delivery of nonhaematopoietic cells in DMD.
Improvement of mesoangioblast extravasation upon modu-
lation of endothelial junctional proteins in dystrophic mice
has been recently published [134] and additional strategies
to translate mesoangioblast transplantation to autologous
settings, based upon human artificial chromosomes [135],
reversible cell immortalization (Benedetti et al., in prepara-
tion) and differentiation of iPS cells [92, 136] are currently
under development.
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7. Conclusions
Stem cell transplantation for muscle disorders has faced
several hurdles since the first trials more than 20 years ago.
Progress has been made and myogenic stem cells other than
myoblasts have entered clinical experimentation. Neverthe-
less, understanding what are the key factors allowing stable
cell engraftment still remains critical for the success of allo-
geneic or autologous transplants in inflamed muscles. Clear
immunological characterisation of stem cells (particularly
when derived from pluripotent stem cells) together with a
deeper understanding of the relevance of preexisting reactive
T cells are issues that are undergoing intense investigation.
Moreover, it is necessary to take into account other complex
matters such as the insurgence of immune responses against
the restored protein (e.g., against dystrophin in DMD) or
against viral elements (in gene therapy settings) that might
appear at different times. All these points add an additional
level of complexity to the analysis of immune responses
in stem cell therapies for muscular dystrophies and might
require interventions beyond immunosuppression, such as
induction of immune tolerance. Models and strategies to
improve the outcome of xenotransplantation in immunodefi-
cient animals will also be required in order to develop assays
powerful enough to assess safety and efficacy of different
types of myogenic stem cells. Even in such a case, some
of the information necessary for the refinement of complex
therapies (such as those based upon stem cells) will inevitably
be unpredictable. However, prompt bedside-to-bench studies
will bring invaluable insights to the field and, hopefully,
efficacious solutions.
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